Notably, the ROR-γ-selective antagonists XY018 and SR2211 block the growth of prostate cancer cells with androgen receptor expression and restore sensitivity to enzalutamide treatment (a commonly used androgen inhibitor for prostate cancer), in which induction of apoptosis and decreased expression of key proliferation and survival proteins were identified as key events [278]. This evidence concerns the gene RORC and Familial prostate cancer.